HTA3 Passport for Travel: Proposed Framework for Transportability of Oncology Real World Evidence

There is an increased demand for oncology RWD to support decision-making by health-technology assessment (HTA) bodies, particularly when there is a lack of long-term comparative data. The extent to which insights generated from US RWD should be used to address uncertainty in ex-US markets is commonly questioned. This study aimed to identify challenges in assessing the transportability of evidence derived from real-world US electronic health records (EHR) and proposes a framework for mitigating risks to HTA decision-makers.